255 related articles for article (PubMed ID: 33818540)
1. A challenging frontier - the genomics and therapeutics of nonclear cell renal cell carcinoma.
Patel HV; Srivastava A; Srinivasan R; Singer EA
Curr Opin Oncol; 2021 May; 33(3):212-220. PubMed ID: 33818540
[TBL] [Abstract][Full Text] [Related]
2. Metastatic nonclear renal cell carcinoma current review in evolving treatment strategies.
Suárez C; Díaz-Mejía N; Morales-Barrera R; González M; Mateo J; Carles J
Curr Opin Urol; 2021 May; 31(3):242-248. PubMed ID: 33742977
[TBL] [Abstract][Full Text] [Related]
3. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.
Voss MH; Bastos DA; Karlo CA; Ajeti A; Hakimi AA; Feldman DR; Hsieh JJ; Molina AM; Patil S; Motzer RJ
Ann Oncol; 2014 Mar; 25(3):663-668. PubMed ID: 24458473
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint inhibitors in metastatic papillary renal cell carcinoma.
de Vries-Brilland M; McDermott DF; Suárez C; Powles T; Gross-Goupil M; Ravaud A; Flippot R; Escudier B; Albigès L
Cancer Treat Rev; 2021 Sep; 99():102228. PubMed ID: 34111642
[TBL] [Abstract][Full Text] [Related]
5. Savolitinib for MET-driven papillary renal cell carcinoma.
Gilbert JA
Lancet Oncol; 2017 Aug; 18(8):e440. PubMed ID: 28669737
[No Abstract] [Full Text] [Related]
6. Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.
Feldman DR; Ged Y; Lee CH; Knezevic A; Molina AM; Chen YB; Chaim J; Coskey DT; Murray S; Tickoo SK; Reuter VE; Patil S; Xiao H; Aghalar J; Apollo AJ; Carlo MI; Motzer RJ; Voss MH
Cancer; 2020 Dec; 126(24):5247-5255. PubMed ID: 32975815
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Patients With Advanced Renal Cell Carcinoma With Non-Clear Cell Histology Treated With Systemic Therapy.
Urman D; Deshler L; Weise N; Shabaik A; Derweesh I; Bagrodia A; Rose B; Herchenhorn D; McKay RR
Clin Genitourin Cancer; 2023 Dec; 21(6):660-668.e1. PubMed ID: 37858374
[TBL] [Abstract][Full Text] [Related]
8. The roaring 2020s: a new decade of systemic therapy for renal cell carcinoma.
Srivastava A; Doppalapudi SK; Patel HV; Srinivasan R; Singer EA
Curr Opin Oncol; 2022 May; 34(3):234-242. PubMed ID: 35266906
[TBL] [Abstract][Full Text] [Related]
9. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma.
Bersanelli M; Rebuzzi SE; Roviello G; Catalano M; Brunelli M; Rizzo M
Hum Vaccin Immunother; 2023 Dec; 19(1):2171672. PubMed ID: 36758960
[TBL] [Abstract][Full Text] [Related]
11. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
[TBL] [Abstract][Full Text] [Related]
12. Current and future strategies in nonclear-cell metastatic renal cell carcinoma.
Albiges L; Escudier B
Curr Opin Urol; 2015 Sep; 25(5):367-73. PubMed ID: 26153638
[TBL] [Abstract][Full Text] [Related]
13. Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade.
Motzer RJ; Banchereau R; Hamidi H; Powles T; McDermott D; Atkins MB; Escudier B; Liu LF; Leng N; Abbas AR; Fan J; Koeppen H; Lin J; Carroll S; Hashimoto K; Mariathasan S; Green M; Tayama D; Hegde PS; Schiff C; Huseni MA; Rini B
Cancer Cell; 2020 Dec; 38(6):803-817.e4. PubMed ID: 33157048
[TBL] [Abstract][Full Text] [Related]
14. Evolving therapeutic targets in renal cell carcinoma.
Singer EA; Gupta GN; Marchalik D; Srinivasan R
Curr Opin Oncol; 2013 May; 25(3):273-80. PubMed ID: 23455028
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology.
Su D; Singer EA; Srinivasan R
Curr Opin Oncol; 2015 May; 27(3):217-23. PubMed ID: 25811348
[TBL] [Abstract][Full Text] [Related]
16. Papillary renal cell carcinoma: A review of the current therapeutic landscape.
Courthod G; Tucci M; Di Maio M; Scagliotti GV
Crit Rev Oncol Hematol; 2015 Oct; 96(1):100-12. PubMed ID: 26052049
[TBL] [Abstract][Full Text] [Related]
17. Investigational MET inhibitors to treat Renal cell carcinoma.
Nandagopal L; Sonpavde GP; Agarwal N
Expert Opin Investig Drugs; 2019 Oct; 28(10):851-860. PubMed ID: 31554440
[No Abstract] [Full Text] [Related]
18. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
Abdelaziz A; Vaishampayan U
Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
[TBL] [Abstract][Full Text] [Related]
19. Genomic profiling in renal cell carcinoma.
Dizman N; Philip EJ; Pal SK
Nat Rev Nephrol; 2020 Aug; 16(8):435-451. PubMed ID: 32561872
[TBL] [Abstract][Full Text] [Related]
20. Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches.
Linehan WM; Srinivasan R; Garcia JA
Semin Oncol; 2013 Aug; 40(4):511-20. PubMed ID: 23972715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
